Tadayoshi Hashimoto

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 15

Top Topics

Locally Advanced

Tyrosine Kinase

Top Venues

International journal of clinical oncology

Future oncology (London, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Tadayoshi Hashimoto, Yoshiaki Nakamura, Saori Mishima, Izuma Nakayama, Daisuke Kotani, Akihito Kawazoe, Yasutoshi Kuboki, Hideaki Bando, Takashi Kojima, Naoko Iida, Taro Shibuki, Mitsuho Imai, Takao Fujisawa, Michiko Nagamine, Naoya Sakamoto, Takeshi Kuwata, Takayuki Yoshino, Kohei Shitara
Whole-transcriptome sequencing in advanced gastric or gastroesophageal cancer: A deep dive into its clinical potential. Cancer science 115 (5) (2024)
Tadayoshi Hashimoto, Yoshiaki Nakamura, Saori Mishima, Izuma Nakayama, Daisuke Kotani, Akihito Kawazoe, Yasutoshi Kuboki, Hideaki Bando, Takashi Kojima, Naoko Iida, Taro Shibuki, Mitsuho Imai, Takao Fujisawa, Michiko Nagamine, Naoya Sakamoto, Takeshi Kuwata, Takayuki Yoshino, Kohei Shitara
Whole-transcriptome sequencing in advanced gastric or gastroesophageal cancer: A deep dive into its clinical potential. Cancer science 115 (5) (2024)
Tadayoshi Hashimoto, Yoshiaki Nakamura, Eiji Oki, Shin Kobayashi, Junichiro Yuda, Taro Shibuki, Hideaki Bando, Takayuki Yoshino
Bridging horizons beyond CIRCULATE-Japan: a new paradigm in molecular residual disease detection via whole genome sequencing-based circulating tumor DNA assay. International journal of clinical oncology 29 (5) (2024)
Tadayoshi Hashimoto, Yoshiaki Nakamura, Eiji Oki, Shin Kobayashi, Junichiro Yuda, Taro Shibuki, Hideaki Bando, Takayuki Yoshino
Bridging horizons beyond CIRCULATE-Japan: a new paradigm in molecular residual disease detection via whole genome sequencing-based circulating tumor DNA assay. International journal of clinical oncology 29 (5) (2024)
Tadayoshi Hashimoto, Yoshiaki Nakamura, Saori Mishima, Izuma Nakayama, Daisuke Kotani, Akihito Kawazoe, Yasutoshi Kuboki, Hideaki Bando, Takashi Kojima, Naoko Iida, Taro Shibuki, Mitsuho Imai, Takao Fujisawa, Michiko Nagamine, Naoya Sakamoto, Takeshi Kuwata, Takayuki Yoshino, Kohei Shitara
Whole-transcriptome sequencing in advanced gastric or gastroesophageal cancer: A deep dive into its clinical potential. Cancer science (2024)
Tadayoshi Hashimoto, Yoshiaki Nakamura, Saori Mishima, Izuma Nakayama, Daisuke Kotani, Akihito Kawazoe, Yasutoshi Kuboki, Hideaki Bando, Takashi Kojima, Naoko Iida, Taro Shibuki, Mitsuho Imai, Takao Fujisawa, Michiko Nagamine, Naoya Sakamoto, Takeshi Kuwata, Takayuki Yoshino, Kohei Shitara
Whole-transcriptome sequencing in advanced gastric or gastroesophageal cancer: A deep dive into its clinical potential. Cancer science 115 (5) (2024)
Tadayoshi Hashimoto, Yoshiaki Nakamura, Eiji Oki, Shin Kobayashi, Junichiro Yuda, Taro Shibuki, Hideaki Bando, Takayuki Yoshino
Bridging horizons beyond CIRCULATE-Japan: a new paradigm in molecular residual disease detection via whole genome sequencing-based circulating tumor DNA assay. International journal of clinical oncology 29 (5) (2024)
Tadayoshi Hashimoto, Yoshiaki Nakamura, Takao Fujisawa, Mitsuho Imai, Taro Shibuki, Naoko Iida, Hiroshi Ozaki, Norio Nonomura, Chigusa Morizane, Hiroji Iwata, Susumu Okano, Wataru Yamagami, Naoya Yamazaki, Shigenori Kadowaki, Hiroya Taniguchi, Makoto Ueno, Shogen Boku, Eiji Oki, Yoshito Komatsu, Satoshi Yuki, Akitaka Makiyama, Tomoyuki Otsuka, Hiroki Hara, Naohiro Okano, Tomohiro Nishina, Yasutoshi Sakamoto, Izumi Miki, Shin Kobayashi, Junichiro Yuda, Shun-Ichiro Kageyama, Michiko Nagamine, Shingo Sakashita, Naoya Sakamoto, Riu Yamashita, Yoshikatsu Koga, Hideaki Bando, Genichiro Ishii, Takeshi Kuwata, Woong-Yang Park, Atsushi Ohtsu, Takayuki Yoshino
The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine. Cancer discovery (2024)
Tadayoshi Hashimoto, Yoshiaki Nakamura, Eiji Oki, Shin Kobayashi, Junichiro Yuda, Taro Shibuki, Hideaki Bando, Takayuki Yoshino
Bridging horizons beyond CIRCULATE-Japan: a new paradigm in molecular residual disease detection via whole genome sequencing-based circulating tumor DNA assay. International journal of clinical oncology 29 (5) (2024)
Tadayoshi Hashimoto, Yoshiaki Nakamura, Eiji Oki, Shin Kobayashi, Junichiro Yuda, Taro Shibuki, Hideaki Bando, Takayuki Yoshino
Bridging horizons beyond CIRCULATE-Japan: a new paradigm in molecular residual disease detection via whole genome sequencing-based circulating tumor DNA assay. International journal of clinical oncology (2024)
Tadayoshi Hashimoto, Yuichiro Tsukada, Masaaki Ito, Keisuke Kanato, Junki Mizusawa, Haruhiko Fukuda, Shunsuke Tsukamoto, Atsuo Takashima, Yukihide Kanemitsu
Utility of circulating tumour DNA for prognosis and prediction of therapeutic effect in locally recurrent rectal cancer: study protocol for a multi-institutional, prospective observational study (JCOG1801A1, CAP-LR study). BMJ open 13 (8) (2023)
Tadayoshi Hashimoto, Satoshi Otsu, Shuichi Hironaka, Atsuo Takashima, Junki Mizusawa, Tomoko Kataoka, Haruhiko Fukuda, Shunsuke Tsukamoto, Tetsuya Hamaguchi, Yukihide Kanemitsu
Phase II biomarker identification study of anti-VEGF agents with FOLFIRI for pretreated metastatic colorectal cancer. Future oncology (London, England) (2023)
Tadayoshi Hashimoto, Shunsuke Tsukamoto, Keiko Murofushi, Yoshinori Ito, Hidekazu Hirano, Yuichiro Tsukada, Keita Sasaki, Junki Mizusawa, Haruhiko Fukuda, Atsuo Takashima, Yukihide Kanemitsu
Total neoadjuvant therapy followed by a watch-and-wait strategy for patients with rectal cancer (TOWARd): protocol for single-arm phase II/III confirmatory trial (JCOG2010). BJS open 7 (6) (2023)
Tadayoshi Hashimoto, Satoshi Maruyama, Yasumasa Takii, Junki Mizusawa, Tomoko Kataoka, Haruhiko Fukuda, Shunsuke Tsukamoto, Atsuo Takashima, Tetsuya Hamaguchi, Yukihide Kanemitsu
A randomized phase II study comparing preoperative mFOLFOX6 versus FOLFOXIRI for locally advanced colon cancer: JCOG2006. Future oncology (London, England) (2023)
Tadayoshi Hashimoto, Izuma Nakayama, Manabu Ohashi, Junki Mizusawa, Hiroshi Kawachi, Ryosuke Kita, Haruhiko Fukuda, Yukinori Kurokawa, Narikazu Boku, Takaki Yoshikawa, Masanori Terashima
Randomized phase II study comparing neoadjuvant 5-fluorouracil/oxaliplatin/docetaxel versus docetaxel/oxaliplatin/S-1 for patients with type 4 or large type 3 gastric cancer. Future oncology (London, England) (2023)